Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase III study investigates phosphate-lowering effects of SBR-759

Nov. 25, 2011

Favorable preclinical results reported for Shionogi's new anti-atherosclerotic agent

Nov. 25, 2011

New anticoagulants show promise in proof-of-concept studies in vivo

Nov. 25, 2011

Preclinical and clinical results reported for Myrexis oncolytic compounds

Nov. 25, 2011

Melphalan flufenamide evaluated in phase I/IIa study

Nov. 25, 2011

Amgen tests antibody-drug conjugate targeting EGFRvIII

Nov. 24, 2011

Updated results presented from ongoing first-in-patient trial of PF-04691502

Nov. 24, 2011

Results reported from phase I trial of enavatuzumab in advanced solid tumors

Nov. 24, 2011

Korean investigators discover new biomarker of disease activity in rheumatoid arthritis

Nov. 24, 2011

New LXR agonist displays promising antiatherosclerotic effects in vivo

Nov. 24, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...